ACIPHEX

This brand name is authorized in United States, South Africa

Active ingredients

The drug ACIPHEX contains one active pharmaceutical ingredient (API):

1 Rabeprazole UNII 3L36P16U4R - RABEPRAZOLE SODIUM

Rabeprazole belongs to the class of anti-secretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonist properties, but suppress gastric acid secretion by the specific inhibition of the H+/K+ -ATPase enzyme (the acid or proton pump). Read about Rabeprazole

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ACIPHEX Delayed-release tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR
ACIPHEX SPRINKLE Delayed-release capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A02BC04	Rabeprazole	A Alimentary tract and metabolism → A02 Drugs for acid related disorders → A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) → A02BC Proton pump inhibitors
Discover more medicines within A02BC04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 23594-205, 23594-210, 62856-243
Country: ZA	Health Products Regulatory Authority	Identifier(s): A39/11.4.3/0468, A39/11.4.3/0469